Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Chinese Patent Office
US Department of Justice
Johnson and Johnson

Generated: March 18, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 011287

« Back to Dashboard

NDA 011287 describes KAYEXALATE, which is a drug marketed by Concordia Pharms Inc and is included in one NDA. It is available from two suppliers. Additional details are available on the KAYEXALATE profile page.

The generic ingredient in KAYEXALATE is sodium polystyrene sulfonate. There are one thousand four hundred and fifteen drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the sodium polystyrene sulfonate profile page.
Summary for 011287
Applicant:Concordia Pharms Inc
Ingredient:sodium polystyrene sulfonate
Therapeutic Class:Antidotes, Deterrents, and Toxicologic Agents
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 011287
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
KAYEXALATE sodium polystyrene sulfonate POWDER;ORAL, RECTAL 011287 NDA Covis Pharmaceuticals, Inc. 24987-075 E 24987-075-01
KAYEXALATE sodium polystyrene sulfonate POWDER;ORAL, RECTAL 011287 NDA Concordia Pharmaceuticals Inc. 59212-075 N 59212-075-01

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:POWDER;ORAL, RECTALStrength453.6GM/BOT
Approval Date:Approved Prior to Jan 1, 1982TE:RLD:Yes

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Federal Trade Commission
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.